Pradhan, R. ., Yin, H. ., Lu, S. ., Sebastiani, G. ., Yu, O. ., Suissa, S. ., & Azoulay, L. . (2025). Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc24-1903
O. Yu
First name
O.
Last name
Yu
Simms-Williams, N. ., Treves, N. ., Yin, H. ., Lu, S. ., Yu, O. ., Pradhan, R. ., … Azoulay, L. . (2024). Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. Bmj, 385, e078242. http://doi.org/10.1136/bmj-2023-078242
Pradhan, R. ., Yin, H. ., Yu, O. ., & Azoulay, L. . (2022). Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc21-1953
Pradhan, R. ., Yu, O. ., Platt, R. W., & Azoulay, L. . (2022). Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. Diabetes Res Clin Pract, 185, 109229. http://doi.org/10.1016/j.diabres.2022.109229
Yu, O. ., Azoulay, L. ., Yin, H. ., Filion, K. B., & Suissa, S. . (2018). Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. Am J Med. http://doi.org/10.1016/j.amjmed.2017.09.044